Gilead Analyst Sees Only 50% Chance That Coronavirus Drug Works
This article is for subscribers only.
One of Gilead Sciences Inc.’s biggest bulls says the drugmaker’s experimental therapy for coronavirus has at best a 50/50 shot at success.
Developing a treatment for the deadly virus “remains a somewhat risky, unclear opportunity,” RBC analyst Brian Abrahams wrote in a note. While the need for medicines sets the bar very low for Gilead’s remdesivir, prior disappointments in Ebola, confounding data and limited dosing results add to risks.